Amy A. Hassan, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Chair, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Chair, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2001 | Baylor College of Medicine, Houston, Texas, US, Doctor of Medicine |
| 1997 | Rice University, Houston, Texas, US, Biology and French, Bachelor of Arts |
Postgraduate Training
| 2004-2007 | Clinical Fellowship, Hematology and Oncology, Baylor College of Medicine, Houston, Texas |
| 2001-2004 | Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, Texas |
Licenses & Certifications
| 2007 | American Board of Internal Medicine - Medical Oncology |
| 2007 | American Board of Internal Medicine - Hematology |
| 2005 | Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Chair, Ad Interim, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2025
Associate Professor, General Internal Medicine, The University of Texas Medical Branch, Galveston, TX, 2018 - 2025
Associate Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2020
Assistant Professor, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2014
Administrative Appointments/Responsibilities
Chair, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2026 - Present
Chair, Ad Interim, General Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2025
Co-Chair, Clinical Governance/ Operational Structure, Subcommittee of Services Collaboration Committee, The University of Texas MD Anderson Cancer Center and UTMB, League City, TX, 2019 - 2020
Center Medical Director, Houston Area Locations - League City, The University of Texas MD Anderson Cancer Center, League City, TX, 2017 - 2020
Safety Officer, Houston Area Locations - League City, The University of Texas MD Anderson Cancer Center, League City, TX, 2017 - 2019
Patient Experience Officer, Houston Area Locations - League City, The University of Texas MD Anderson Cancer Center, League City, TX, 2017 - 2019
Section Chief, Bay Area Regional Care Center, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2017
Chief Fellow, Baylor College of Medicine, Houston, TX, 2006 - 2007
Other Professional Positions
Oncology Pathway Panel Consultant, Carelon Medical Benefits Management, Chicago, IL, 2015 - Present
Extramural Institutional Committee Activities
Co-Chair, Institutional Committee Breast Medical Oncology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2025
Member, Regional Incentive Review Task Force, The University of Texas MD Anderson Cancer Center, 2025 - Present
Member, Executive Leadership Team - UTMB Transition, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, UTMB-MDA Transition Team, The University of Texas MD Anderson Cancer Center, 2024 - Present
Committee Member, Ambulatory Core Clinical Leadership Team, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, One MD Anderson Task Force, Finance Analytics and Compensation Working Group, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Co-Lead, Access Redesign Initiative, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2023
Executive Committee Member, National Clinical Trials Network Leading Academic Participating Sites, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Division of Cancer Medicine Executive Council, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, ATC Optimization Committee, The University of Texas MD Anderson Cancer Center, 2019 - 2020
Member, Houston Area Locations Quality and Safety Council, The University of Texas MD Anderson Cancer Center, 2018 - 2020
Member, Regional Practice Committee Subcommittee of Executive Clinical Operations Team, The University of Texas MD Anderson Cancer Center, 2017 - 2020
Member, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2010 - 2013
Honors & Awards
| 2024 | Top 10% Providers, Clinician and Group Consumer Assessment of Healthcare Providers and Systems Survey |
| 2023 | Excellence in LEADership Award, The University of Texas MD Anderson Cancer Center |
| 2018 | Top 10% Providers, Clinician and Group Consumer Assessment of Healthcare Providers and Systems Survey |
| 2004 | Outstanding Achievement in Ambulatory Medicine |
| 2000 | Nominated to Alpha Omega Alpha |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. Safety Moment: The Importance of Psychological Safety. Invited. Leadership Day 2025, Bayou City Event Center. Houston, Texas, US.
- 2008. Malignant Hematology Question and Answer Session. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2006. Magnetic resonance imaging with gadolinium-filled carbon nanotubes. Conference. Baylor College of Medicine - Second Annual Breast Program Retreat, US.
Formal Peers
- 2021. Breast Cancer: Risk Reduction and New Treatments. Invited, US.
- 2018. Healthy Choices Help Lower Your Cancer Risk. Invited. Seabrook, TX, US.
- 2017. Updates in Oncology Treatment. Invited. Nassau Bay, TX, US.
- 2017. Breast Cancer Treatment in 2017. Invited. Houston, TX, US.
- 2013. Hormonal Agents in the Treatment of Breast Cancer, Cancer Therapeutics Continuing Education Lecture Series. Visiting, US.
- 2012. Overview of lymphomas. Invited. Nassau Bay, TX, US.
- 2011. Breast Cancer: Know Your Risks. Know Your History. Invited. League City, TX, US.
- 2010. Myelodysplastic syndrome. Invited. Nassau Bay, TX, US.
- 2009. Skin Cancer Prevention. Invited. Houston, TX, US.
- 2009. Cancer Prevention and Screening. Invited. Pearland, TX, US.
- 2008. Oncologic Emergencies. Invited. Nassau Bay, TX, US.
- 2008. Cancer Prevention and Screening. Invited. League City, TX, US.
Grant & Contract Support
| Date: | 2019 - 2025 |
| Title: | UT MD Anderson Cancer Center Network Lead Academic Participating Site (LAP) |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5UG1 CA233329-06 |
Selected Publications
Peer-Reviewed Articles
- Mouabbi JA, Raghavendra AS, Bassett RL, Christgen M, Middleton L, Teshome M, Nasrazadani A, Hortobagyi G, Hassan A, Tripathy D, Layman RM. Absence of lobular carcinoma in situ is a poor prognostic marker in invasive lobular carcinoma. Eur J Cancer 191:113250, 2023. e-Pub 2023. PMID: 37573674.
- Mouabbi JA, Singareeka Raghavendra A, Bassett RL, Hassan A, Tripathy D, Layman RM. Survival Outcomes in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy. JAMA Netw Open 6(5):e2313017, 2023. e-Pub 2023. PMID: 37166793.
- Mouabbi JA, Raghavendra AS, Bassett RL, Hassan A, Tripathy D, Layman RM. Histology-based survival outcomes in hormone receptor-positive metastatic breast cancer treated with targeted therapies. NPJ Breast Cancer 8(1):131, 2022. e-Pub 2022. PMID: 36539444.
- Hassan AA, Chan BT, Tran LA, Hartman KB, Ananta JS, Mackeyev Y, Hu L, Pautler RG, Wilson LJ, Lee AV. Serine-derivatized gadonanotubes as magnetic nanoprobes for intracellular labeling. Contrast Media Mol Imaging 5(1):34-8, 2010. e-Pub 2010. PMID: 20101755.
Invited Articles
- Hassan A, Kroll MH. Acquired disorders of platelet function. Hematology Am Soc Hematol Educ Program:403-8, 2005. e-Pub 2005. PMID: 16304411.
Review Articles
- Mouabbi JA, Hassan A, Lim B, Hortobagyi GN, Tripathy D, Layman RM. Invasive lobular carcinoma: an understudied emergent subtype of breast cancer. Breast Cancer Res Treat 193(2):253-264, 2022. e-Pub 2022. PMID: 35347549.
Book Chapters
- Kroll MH, Hassan A. Acquired Disorders of Platelet Function. In: Gresele P, Fuster V, Lopez JA, Page CP, Vermylen J, eds. In: Platelets in Cardiovascular and Hematologic Disorders: A Clinical Handbook. Cambridge University Press, 225-41, 2008.
Patient Reviews
CV information above last modified July 22, 2026